Chemistry:Tirabrutinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Velexbru |
| Other names | GS-4059; ONO-4059 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H22N6O3 |
| Molar mass | 454.490 g·mol−1 |
Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies.[1][2]
Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma.[1] In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences[3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis.[1]
Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase.[4]
References
- ↑ 1.0 1.1 1.2 "Tirabrutinib: First Approval". Drugs 80 (8): 835–840. June 2020. doi:10.1007/s40265-020-01318-8. PMID 32382949.
- ↑ "Tirabrutinib". NCI Drug Dictionary. National Institutes of Health. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tirabrutinib.
- ↑ "Tirabrutinib - Gilead Sciences/Ono Pharmaceutical". Adis Insight. https://adisinsight.springer.com/drugs/800036049.
- ↑ "Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition". Biochimica et Biophysica Acta (BBA) - General Subjects 1864 (4): 129531. April 2020. doi:10.1016/j.bbagen.2020.129531. PMID 31953125.
 |  |
